Dyslipidemia And Dysglycemia In Patients With HIV Infection and In Patients On Antiretroviral Therapy
Dyslipidemia And Dysglycemia In Patients With HIV
DOI:
https://doi.org/10.70284/njirm.v3i5.2100Keywords:
ART-anti retroviral therapy, acquired Immuno deficiency syndrome –AIDS, human immunodeficiency virus -HIVAbstract
Objective: Use of ART in HIV infected individuals’ results in reduced mortality and morbidity associated with AIDS. Long term complications of HIV & ART including dyslipidemia & dysglycemia have raise concern regarding accelerated cardiovascular risk in these patients. Aim of study is to determine prevalence of dyslipidemia & dysglycemia in HIV infected patients and its relation to CD 4 count. Material and Methods: A cross sectional two arm comparison study carried out at Shree Sayajirao General Hospital and Medical College Baroda. The treatment arm, ON ART arm, constituted 30 patients already on ART defined as a combination of at least three classes of antiretroviral drugs, namely PIs, NNRTIs and NRTIs, one of which was a PI or an NNRTI ,or a triple combination of NRTIs. Comparator arm, ART naïve arm constituted 30 HIV-positive patients, eligible for, but not yet receiving ART. Dyslipidemia & dysglycemia were defined as high total or LDL cholesterol, high triglycerides, or low HDL cholesterol according to the adult treatment panel III (ATP III) guidelines and as the presence of diabetes , impaired fasting blood sugar(FBS) , impaired post prandial blood sugar(PP2BS) or impaired glucose tolerance according to ADA (American diabetes association)criteria ,respectively. Discussion: Dysglycemia was present in 30% of study population and dyslipidemia was present in 73.33% of study population. Difference in elevation of serum Cholesterol level and serum LDL level in patients on ART arm was statistically significant. Dysglycemia and dyslipidemia was associated with low CD 4 count compare to patients with normal blood glucose level and normal lipid profile level.
References
2. Epidemiology and pathogenesis of dyslipidemia and cardiovascular disease in HIV-infected patients Authors Sanjivini G Wadhwa, MD Sandip K Mukherjee, MD, FACC Section Editor at el,buffalo,Last literature review version 17.1: January 2009
3. Prevalence of Dyslipidemia and Metabolic Abnormalities in HIV-Infected Patients Amitis Ramezani1,3, Minoo Mohraz2, 1 Department of Clinical Research, Pasteur Institute of Iran, 2 Iranian Research Center for HIV/AIDS, 3 Infectious Diseases Research center, Tehran, Iran. 2007
4. Coronary Heart Disease (CHD) Risk Factors and Metabolic Syndrome in HIV-Positive in Miami ;Florida International University, College of Health and Urban Affairs University of Miami School of Medicine, Miami, Florida Johns Hopkins University, Baltimore, Maryland.
5. Metabolic Syndrome in HIV infected patients, carlos jerico at el ,Diabetes care ,volume 28 ,January 2005.
6. Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors From the Division of Infectious Diseases (D.P., A.T., P.H., M.P.G.),BH 19-135, CHUV University Hospital, CH-1011 CHUV Lausanne, Switzerland. E-mail vincent.mooser@hola.hos
7. Metabolic Syndrome, Cardiovascular Disease and Type 2 Diabetes Mellitus After Initiation of Antiretroviral Therapy in HIV Infection,Handan Wand at el; Posted: 11/29/2007; AIDS. Lippincott Williams & Wilkins
8. JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 July 2008 - Volume 48 - Issue 3 - pp272280doi:10.1097/QAI.0b013e31817af461 Clinical Science;Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected woman.
9. Prevalence of dyslipidemia and dysglycemia in HIV-infected patients Authors: EM Manuthu, M D Joshi, G N Lule, and E Karari Reference: East African Medical Journal 2008; 85(1): 10 Kenyatta National Hospital, Kenya
10. Insight Into the Burden of Coronary Artery Disease in HIV-Infected Patients Coverage provided by Margaret Hoffman-Terry, M.D., F.A.C.P.July 24, 2007
